 Valeant Pharmaceuticals International Inc. said its second-quarter profit and sales climbed amid strong growth in almost all of its businesses, as the company again made a case to buy Botox maker Allergan Inc.. But Valeant lowered its revenue and earnings-per-share guidance for the year to reflect the sale of its facial-injectables business, among other items.. Valeant...
  